Sequent Scientific Ltd

SEQUENT

Watchlist

AI Mode

‌

Market Cap

₹ 5,355 Cr

P/E

122.53

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

OVERVALUED

Growth

SLUGGISH

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

HIGH RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Sequent Scientific Limited is an animal health-focused life sciences company, specializing in Active Pharmaceutical Ingredients (APIs) and formulations for animal health. The company has demonstrated strong revenue growth, achieving a 15% year-on-year increase, driven by formulation business expansion and strategic geographic growth.

Sequent's merger with Viyash Life Sciences significantly contributes to improved gross margins and synergies across operations, showcasing its strategic intent to expand and enhance its market position in the life sciences sector.

Sequent has leveraged its strong R&D capabilities to launch new products and engage in API and formulation optimization, positioning itself for sustained growth and profitability.

The merger enables Sequent to enhance manufacturing capabilities and realize cost efficiencies, with plans to further penetrate the companion animal market segment, leveraging its expanded operational base.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

5,355 Cr

Volatility

High Risk

P/E Ratio

122.5

Industry P/E

30.7

PEG Ratio

55.9

P/B Ratio

6.6

52W High

260.30

52W Low

111.00

Sales CAGR

13.26%

-6.72%

-4.75%

10Y

-8.81%

Profit CAGR

208.95%

2.19%

-5.84%

10Y

4.77%

ROE

TTM

5.17%

-6.05%

0.03%

10Y

6.48%

ROCE

TTM

10.38%

-0.12%

4.66%

10Y

5.32%

Technicals

Oscillators

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
AKUMS	420.10	6,612 Cr	21.50	2.10	0.00	10.07	8.99	6.27
SUPRIYA	732.50	5,885 Cr	32.27	5.44	0.14	16.86	22.47	15.16
SEQUENT	211.45	5,355 Cr	122.53	6.62	0.00	5.17	10.38	3.13
ZOTA	1654.50	5,111 Cr	—	15.57	0.06	-19.58	-9.69	-10.20
ORCHPHARMA	830.00	4,209 Cr	80.57	3.30	0.00	4.10	4.28	3.02
INNOVACAP	691.25	3,983 Cr	32.00	3.90	0.00	12.19	13.06	7.36
SUVEN	171.60	3,911 Cr	—	13.91	0.00	-75.33	-75.33	-62.80

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	333	346	329	361	390	369	391	402	441	424
Expenses	341	331	307	329	348	330	356	355	389	368
Operating Profit	-8.24	15	22	32	42	39	35	46	52	56
OPM %	-2.47	4.37	6.76	8.93	10.75	10.61	8.83	11.51	11.82	13.13
Other Income	-23	9.72	7.28	-0.71	2.68	0.19	5.53	1.32	2.62	0.45
Interest	10	13	13	12	16	14	15	15	14	14
Depreciation	14	15	15	16	16	17	17	16	15	15
Profit Before Tax	-56	-3.09	1.49	2.64	12	7.90	8.10	16	26	27
Tax %	37.72	-122.65	-616.78	51.89	24.50	19.75	20.00	36.36	31.15	27.84
Net Profit	-35	-6.88	11	1.27	9.06	6.34	6.48	10	18	20
EPS in Rs	-1.39	-0.34	0.33	-0.04	0.26	0.10	0.13	0.37	0.56	0.58

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	689	849	1,039	1,179	1,362	1,413	1,421	1,370	1,551	1,603
Expenses	641	765	914	1,009	1,150	1,303	1,409	1,308	1,390	1,431
Operating Profit	48	85	125	170	212	109	12	61	162	172
OPM %	7.02	9.96	12.02	14.44	15.57	7.74	0.84	4.48	10.43	10.73
Other Income	11	15	8.67	10	-0.46	11	-58	-6.43	9.71	9.66
Interest	28	33	33	36	24	16	36	48	61	59
Depreciation	40	41	42	51	51	52	56	62	66	65
Profit Before Tax	-14	24	59	94	137	53	-138	-55	44	58
Tax %	3.66	56.91	3.41	12.79	23.55	15.43	11.39	45.81	27.19	29.50
Net Profit	-14	10	57	82	104	45	-122	-30	32	41
EPS in Rs	-0.55	1.00	1.95	2.82	4.03	1.63	-4.84	-1.44	0.85	1.63
Dividend Payout %	0.00	1.16	10.05	0.00	12.99	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	48	49	49	49	50	50	50	50	50	50
Reserves	898	928	599	657	637	678	642	649	607	654
Borrowings	267	360	256	275	297	277	365	444	488	481
Other Liabilities	315	568	439	406	478	388	394	387	396	416
Total Liabilities	1,528	1,905	1,343	1,388	1,463	1,393	1,451	1,529	1,540	1,602
Fixed Assets	586	684	476	498	577	536	564	605	592	586
CWIP	24	33	18	23	13	31	12	55	16	16
Investments	428	428	239	180	171	83	38	0.05	3.51	0.07
Other Assets	491	760	610	687	701	744	837	868	929	1,000
Total Assets	1,528	1,905	1,343	1,388	1,463	1,393	1,451	1,529	1,540	1,602

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-0.05	-7.19	45	116	115	115	31	17	31	83
Cash from Investing Activity	-310	-116	7.17	-68	-72	9.65	-94	-65	-5.92	-25
Cash from Financing Activity	309	147	-57	-20	-43	-139	67	32	-1.44	-61
Net Cash Flow	-1.82	24	-4.55	28	0.31	-14	3.75	-16	23	-2.15

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	53.00%	53.00%	53.00%	53.00%	52.88%	52.88%	52.87%	52.85%	52.70%	52.70%	52.69%	52.41%
FIIs	6.28%	5.92%	6.29%	6.05%	6.13%	6.17%	5.71%	6.46%	6.11%	6.06%	6.16%	5.91%
DIIs	2.82%	2.93%	2.93%	3.24%	7.24%	7.60%	8.07%	10.01%	12.03%	12.84%	13.01%	12.93%
Public	37.91%	38.15%	37.79%	37.71%	33.75%	33.34%	33.35%	30.68%	29.16%	28.40%	28.14%	28.74%
Total Shareholders	1,96,231	1,91,875	1,87,474	1,84,521	1,72,853	1,66,593	1,63,693	1,54,603	1,62,574	1,58,152	1,47,320	1,44,085

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Oct 01, 2024	Hrti private limited	Bulk	Buy	231.41	24.56 Cr	10,61,489	0.42
Oct 01, 2024	Hrti private limited	Bulk	Sell	231.43	29.68 Cr	12,82,472	0.51
Sep 30, 2024	Hrti private limited	Bulk	Sell	228.93	43.91 Cr	19,18,152	0.76
Sep 30, 2024	Hrti private limited	Bulk	Buy	228.76	40.85 Cr	17,85,553	0.71
Sep 27, 2024	Hrti private limited	Bulk	Buy	213.03	63.26 Cr	29,69,619	1.18
Sep 27, 2024	Qe securities llp	Bulk	Buy	210.14	27.57 Cr	13,11,809	0.52
Sep 27, 2024	Qe securities llp	Bulk	Sell	215.24	28.73 Cr	13,34,977	0.53
Sep 27, 2024	Hrti private limited	Bulk	Sell	214.15	60.30 Cr	28,15,810	1.12
Sep 27, 2024	Ascent india fund iii	Bulk	Sell	195.73	44.72 Cr	22,84,763	0.91
Dec 26, 2023	Sequent scientific employee s...	Insider - Other	Disposal	115.12	6.33 Cr	5,50,000	0.21

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Scheme of Arrangement

16 hours ago

Scheme of Arrangement Update

Sequent Scientific Limited has received regulatory approvals for their composite scheme of amalgamation and has approved the allotment of new equity shares and warrants to shareholders of Viyash.

Change in Directors/KMP

17 hours ago

Management Change Announcement

Sequent Scientific Limited announced a change in management, including new appointments and designations, effective December 16, 2025.

Board Meeting Outcome

17 hours ago

Board Meeting Outcome - Scheme of Amalgamation

The Board of Sequent Scientific Limited approved the Scheme of amalgamation with several companies, including share and warrant allotments effective December 16, 2025.

Equity Allotment

5 days ago

Equity Shares Allotment Under ESOP 2020

Sequent Scientific Limited has approved the allotment of 1,163,301 equity shares under its Employee Stock Option Plan 2020.

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q3 FY24

Investor Presentation

Q2 FY24

Showing 1 - 8 of 13

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode